Health-care companies rose as upward momentum built in one of the strongest 2022 stock-market sectors.

Two biotechnology industry executives, Nader Pourhassan, the former chief executive of CytoDyn, and Kazem Kazempour, whose company managed CytoDyn's clinical drug trials, were indicted on criminal charges based on allegedly misleading claims about an experimental drug, federal prosecutors said.

Pfizer said the Food and Drug Administration and the European Medicines Agency accepted a new drug application for an ulcerative colitis treatment candidate.


Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

12-21-22 1652ET